cancerspЮжно-Российский онкологический журнал/ South Russian Journal of CancerSouth Russian Journal of Cancer2686-9039АНО "Перспективы онкологии"10.37748/2686-9039-2025-6-4-6HQWTVUcancersp-363Research ArticleОБЗОРЫREVIEWSИспользование методов иммунотерапии с применением дендритноклеточных вакцин в онкогинекологииApplication of dendritic cell vaccine immunotherapy in gynecologic malignancieshttps://orcid.org/0000-0001-8832-8219ЖуковаГ. В.ZhukovaG. V.

 

Жукова Галина Витальевна – доктор биологических наук, старший научный сотрудник лаборатории изучения патогенеза злокачественных опухолей ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация

ORCID: https://orcid.org/0000-0001-8832-8219, eLibrary SPIN: 1887-7415, AuthorID: 564827, Scopus Author ID: 7005456284, WoS ResearcherID: Y-4243-2016

 

Galina V. Zhukova – Dr. Sc. (Biology), Senior Researcher at Laboratory of Malignant Tumor Pathogenesis Study, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0001-8832-8219, eLibrary SPIN: 1887-7415, AuthorID: 564827, Scopus Author ID: 7005456284, WoS ResearcherID: Y-4243-2016

galya_57@mail.ruhttps://orcid.org/0000-0003-3618-6890ФранциянцЕ. М.FrantsiyantsE. M.

 

Франциянц Елена Михайловна – д.б.н., профессор, заместитель генерального директора по науке ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация

ORCID: https://orcid.org/0000-0003-3618-6890, eLibrary SPIN: 9427-9928, AuthorID: 462868, Scopus Author ID: 55890047700

 

Elena M. Frantsiyants – Dr. Sci. (Biology), Professor, Deputy General Director for Science, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: http://orcid.org/0000-0003-3618-6890, eLibrary SPIN: 9427-9928, AuthorID: 462868, Scopus Author ID: 55890047700, WoS ResearcherID: Y-1491-2018

super.gormon@yandex.ruhttps://orcid.org/0000-0002-3972-2452КаплиеваИ. В.KaplievaI. V.

 

Каплиева Ирина Викторовна – д.м.н., доцент, заведующий лабораторией изучения патогенеза злокачественных опухолей ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация

ORCID: http://orcid.org/0000-0002-3972-2452, eLibrary SPIN: 5047-1541, AuthorID: 734116, Scopus Author ID:  23994000800, WoS ResearcherID: AAE-3540-2019

 

Irina V. Kaplieva – Dr. Sci. (Medicine), Associate Professor, Head of the Laboratory of Study of Malignant Tumor Pathogenesis, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: http://orcid.org/0000-0002-3972-2452, eLibrary SPIN: 5047-1541, AuthorID: 734116, Scopus Author ID: 23994000800, WoS ResearcherID: AAE-3540-2019

kaplirina@yandex.ruhttps://orcid.org/0000-0002-9683-2164МоисеенкоТ. И.MoiseenkoT. I.

 

Моисеенко Татьяна Ивановна – д.м.н., профессор, главный научный сотрудник отделения гинекологии ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация

ORCID: https://orcid.org/0000-0002-9683-2164, eLibrary SPIN: 6341-0549, AuthorID: 705829, Scopus Author ID: 57194270696

 

Tatiana I. Moiseenko – Dr. Sci. (Medicine), Professor, Chief Researcher, Department of Oncogynecology, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0002-9683-2164, eLibrary SPIN: 6341-0549, AuthorID: 705829, Scopus Author ID: 57194270696

super.gormon@yandex.ruhttps://orcid.org/0000-0002-7968-5078МеньшенинаА. П.MensheninaA. P.

 

Меньшенина Анна Петровна – д.м.н., доцент, ведущий научный сотрудник отделения онкогинекологии ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация

ORCID: http://orcid.org/0000-0002-7968-5078, eLibrary SPIN: 6845-4794, AuthorID: 715810, Scopus Author ID: 57191983118

 

Anna P. Menshenina – Dr. Sci. (Medicine), Accociate Professor, Leading Researcher at the Department of Oncogynecology, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0002-7968-5078, eLibrary SPIN: 6845-4794, AuthorID: 715810, Scopus Author ID: 57191983118

anna.menshenina.00@mail.ruhttps://orcid.org/0000-0003-2943-7655ШихляроваА. И.ShikhlyarovaA. I.

 

Шихлярова Алла Ивановна – д.б.н., профессор, старший научный сотрудник лаборатории изучения патогенеза злокачественных опухолей ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация

ORCID: https://orcid.org/0000-0003-2943-7655, eLibrary SPIN: 6271-0717, AuthorID: 482103, Scopus Author ID: 6507723229, WoS ResearcherID: Y-6275-2018

 

Alla I. Shikhlyarova – Dr. Sci. (Biology), Professor, Senior Researcher, Laboratory of Study of Malignant Tumor Pathogenesis, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0003-2943-7655, eLibrary SPIN: 6271-0717, AuthorID: 482103, Scopus Author ID: 6507723229, WoS ResearcherID: Y-6275-2018

shikhliarova.a@mail.ruhttps://orcid.org/0000-0002-2302-8271БандовкинаВ. А.BandovkinaV. A.

 

Бандовкина Валерия Ахтямовна – д.б.н., ведущий научный сотрудник лаборатории изучения патогенеза злокачественных опухолей ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация

ORCID: https://orcid.org/0000-0002-2302-8271, eLibrary SPIN: 8806-2641, AuthorID: 696989, Scopus Author ID: 57194276288

 

Valerija A. Bandovkina – Dr. Sci. (Biology), Leading Researcher at Laboratory of Malignant Tumor Pathogenesis Study, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0002-2302-8271, eLibrary SPIN: 8806-2641, AuthorID: 696989, Scopus Author ID: 57194276288

valerryana@yandex.ruhttps://orcid.org/0000-0002-4318-7587СуриковаЕ. И.SurikovaE. I.

 

Сурикова Екатерина Игоревна – к.б.н., старший научный сотрудник лаборатории изучения патогенеза злокачественных опухолей ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация

ORCID: https://orcid.org/0000-0002-4318-7587, eLibrary SPIN: 2401-4115, AuthorID: 301537, Scopus Author ID: 6507092816

 

Ekaterina I. Surikova – Cand. Sci. (Biology), Senior Researcher at Laboratory of Malignant Tumor Pathogenesis Study, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0002-4318-7587, eLibrary SPIN: 2401-4115, AuthorID: 301537, Scopus Author ID: 6507092816

sunsur2000@mail.ruhttps://orcid.org/0000-0001-7742-4918ШалашнаяЕ. В.ShalashnayaE. V.

 

Шалашная Елена Владимировна – к.б.н., старший научный сотрудник лаборатории изучения патогенеза злокачественных опухолей ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация

ORCID: http://orcid.org/0000-0001-7742-4918, eLibrary SPIN: 2752-0907, AuthorID: 476958, Scopus Author ID: 55144159900, WoS ResearcherID: AAE-4085-2022

 

Elena V. Shalashnaya – Cand. Sci. (Biology), Senior Researcher, Laboratory of Study of Malignant Tumor Pathogenesis, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: http://orcid.org/0000-0001-7742-4918, eLibrary SPIN: 2752-0907, AuthorID: 476958, Scopus Author ID: 55144159900, WoS ResearcherID: AAE-4085-2022

eshalashnaya@mail.ruhttps://orcid.org/0000-0002-2674-9832ПетроваЮ. А.PetrovaY. A.

 

Петрова Юлия Александровна – к.б.н., старший научный сотрудник лаборатории изучения патогенеза злокачественных опухолей ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация

ORCID: https://orcid.org/0000-0002-2674-9832, eLibrary SPIN: 2168-8737, AuthorID: 558241, Scopus Author ID: 37026863400

 

Yulia A. Petrova – Cand. Sci. (Biology), Senior Researcher at Laboratory of Malignant Tumor Pathogenesis Study, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0002-2674-9832, eLibrary SPIN: 2168-8737, AuthorID: 558241, Scopus Author ID: 37026863400

flora-73@yandex.ruhttps://orcid.org/0000-0001-6928-5014КачесоваП. С.KachesovaP. S.

 

Качесова Полина Сергеевна – к.б.н., научный сотрудник лаборатории изучения патогенеза злокачественных опухолей ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация

ORCID: https://orcid.org/0000-0001-6928-5014, eLibrary SPIN: 5784-0475, Author ID: 571595, Scopus Author ID: 55144158500, WoS ResearcherID: AAF-3998-2019

 

Polina S. Kachesova – Cand. Sci. (Biology), research associate, Laboratory of Study of Malignant Tumor Pathogenesis, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0001-6928-5014, eLibrary SPIN: 5784-0475, Author ID: 571595, Scopus Author ID: 55144158500, WoS ResearcherID: AAF-3998-2019

vnp.kachesova@gmail.comНациональный медицинский исследовательский центр онкологии Министерства здравоохранения Российской Федерации <p> г. Ростов-на-Дону, Российская ФедерацияNational Medical Research Centre for Oncology <p> Rostov-on-Don, Russian Federation202517122025645974Copyright &#x00A9; Жукова Г.В., Франциянц Е.М., Каплиева И.В., Моисеенко Т.И., Меньшенина А.П., Шихлярова А.И., Бандовкина В.А., Сурикова Е.И., Шалашная Е.В., Петрова Ю.А., Качесова П.С., 20252025Жукова Г.В., Франциянц Е.М., Каплиева И.В., Моисеенко Т.И., Меньшенина А.П., Шихлярова А.И., Бандовкина В.А., Сурикова Е.И., Шалашная Е.В., Петрова Ю.А., Качесова П.С.Zhukova G.V., Frantsiyants E.M., Kaplieva I.V., Moiseenko T.I., Menshenina A.P., Shikhlyarova A.I., Bandovkina V.A., Surikova E.I., Shalashnaya E.V., Petrova Y.A., Kachesova P.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.cancersp.com/jour/article/view/363

Разработка методов противоопухолевого лечения, направленных на восстановление системной и локальной иммунной регуляции, рассматривается в качестве наиболее перспективной стратегии в современной онкологии. Большой интерес представляют технологии с использованием дендритноклеточных вакцин (ДКВ), отличающиеся отсутствием токсичности и соответствующие фундаментальным иммунным механизмам противоопухолевой резистентности.

Цель исследования

Цель исследования. Изучить эффективность методов иммунотерапии онкогинекологических заболеваний с использованием ДКВ и перспективные направления их развития.

Материалы и методы

Материалы и методы. Проведен поиск литературы в библиографических реестрах MEDLINE, ClinicalTrial.gov., eLIBRARY и КиберЛенин‑ ка, с использованием поисковых систем PubMed, Google Scholar. Подавляющее большинство источников включены в базы данных Scopus и WoS. В настоящем обзоре рассмотрено более 60 работ на русском и английском языках, более 50 % которых опубликованы в течение последних пяти лет.

Результаты

Результаты. Проанализированы сведения о результатах применения ДКВ при терапии распространенных форм рака шейки матки, рака эндометрия и рака яичников. Положительные эффекты ДКВ включают временную стабилизацию заболевания, увеличение продолжительности и качества жизни при распространенном злокачественном процессе, повышение эффективности химиотерапии после ДКВ, отдельные случаи частичной и полной ремиссии. Рассматривают причины недостаточной эффективности ДКВ, варианты сочетания данной технологии с другими методами иммунотерапии и традиционным противоопухолевым лечением. Невысокая эф‑ фективность ДКВ в отношении онкогинекологических заболеваний на современном этапе может быть обусловлена недостаточной разработанностью технологии и объективными сложностями преодоления механизмов уклонения опухоли от иммунного надзора.

Заключение

Заключение. Потенциал ДКВ как метода противоопухолевого лечения в настоящее время не реализован. Анализ современных достижений в области иммунотерапии, молекулярной биологии, нанотехнологий и подходов к активизации системных и локальных механизмов противоопухолевой резистентности позволяет определить направление дальнейших исследований, нацеленных на повышение эффективности ДКВ как важного компонента комплексного лечения онкогинекологических заболеваний.

The development of antitumor strategies aimed at restoring systemic and local immune regulation is considered one of the most promising directions. Technologies based on dendritic cell vaccines (DCVs), characterized by minimal toxicity and alignment with fundamental immunological mechanisms of antitumor resistance, are of particular interest.

Purpose of the study

Purpose of the study. Is to evaluate the effectiveness of immunotherapeutic approaches for gynecologic malignancies using DCVs and to outline promising directions for further development.

Materials and methods

Materials and methods. A literature search was conducted in the bibliographic registers MEDLINE, ClinicalTrial.gov., eLIBRARY and CyberLeninka, using the search systems PubMed, Google Scholar. The vast majority of the identified sources are indexed in Scopus and Web of Science. The review includes more than 60 publications in Russian and English, over 50 % of which were published within the past five years.

Results

Results. The analysis summarizes data on the clinical outcomes of DCV-based therapy in advanced cervical cancer, endometrial cancer, and ovarian cancer. Reported beneficial effects include temporary disease stabilization, improved overall survival and quality of life in advanced malignancies, enhanced efficacy of subsequent chemotherapy, and occasional cases of partial or complete remission. The review also addresses potential reasons for the limited efficacy of DCVs, as well as possible combinations of this technology with other immunotherapeutic modalities and traditional anticancer treatments. The currently modest therapeutic effectiveness of DCVs in gynecologic cancers may be attributed both to the insufficient maturity of the technology and to inherent mechanisms of tumor immune evasion.

Conclusion

Conclusion. The therapeutic potential of DCVs has not yet been fully realized. Advances in immunotherapy, molecular biology, nanotechnology, and strategies for activating systemic and local antitumor resistance mechanisms provide a foundation for defining future research priorities aimed at improving the efficacy of DCVs as an important component of multimodal treatment for gynecologic malignancies.

иммунотерапиядендритноклеточные вакциныопухолеспецифические иммунные реакциирак шейки маткирак эндометриярак яичниковimmunotherapydendritic cell vaccinestumor-specific immune responsescervical cancerendometrial cancerovarian cancerReferencesHanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12(1):31–46. https://doi.org/10.1158/2159-8290.CD-21-1059Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12(1):31–46. https://doi.org/10.1158/2159-8290.CD-21-1059Кит О. И., Жукова Г. В., Толкачев О. Н., Сидельников Н. И., Фадеев Н. Б., Лукбанова Е. А., Шихлярова А. И. Противоо пухолевые факторы природного происхождения и исследований) некоторые подходы к разработке эффективных схем фитотерапии в онкологии (обзор литературы с включением результатов собственных). Вопросы онкологии. 2022;68(5):527–538. https://doi.org/10.37469/0507-3758-2022-68-5-527-538Kit OI, Zhukova GV, Tolkachev ON, Sidelnikov NI, Fadeev NB, Lukbanova EA, Shikhlyarova AI. Antitumor factors of natural origin and some approaches to the development of effective regimens of phytotherapy in oncology. Problems in Oncology. 2022;68(5):527–538. (In Russ.). https://doi.org/10.37469/0507-3758-2022-68-5-527-538Wu SY, Fu T, Jiang YZ, Shao ZM. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19(1):120. https://doi.org/10.1186/s12943-020-01238-xWu SY, Fu T, Jiang YZ, Shao ZM. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19(1):120. https://doi.org/10.1186/s12943-020-01238-xTao H, Lu L, Xia Y, Dai F, Wang Y, Bao Y, et al. Antitumor effector B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL-10. Eur J Immunol. 2015;45(4):999–1009. https://doi.org/10.1002/eji.201444625Tao H, Lu L, Xia Y, Dai F, Wang Y, Bao Y, et al. Antitumor effector B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL-10. Eur J Immunol. 2015;45(4):999–1009. https://doi.org/10.1002/eji.201444625Yao J, Ji L, Wang G, Ding J. Effect of neutrophils on tumor immunity and immunotherapy resistance with underlying mech anisms. Cancer Commun (Lond). 2025;45(1):15–42. https://doi.org/10.1002/cac2.12613Yao J, Ji L, Wang G, Ding J. Effect of neutrophils on tumor immunity and immunotherapy resistance with underlying mechanisms. Cancer Commun (Lond). 2025;45(1):15–42. https://doi.org/10.1002/cac2.12613Ковалева О. В., Подлесная П. А., Грачев А. Н. Цитотоксическая активность макрофагов и ее роль в патогенезе опухолей. Альманах клинической медицины. 2022;50(1):13–20. https://doi.org/10.18786/2072-0505-2022-50-008Kovaleva OV, Podlesnaya PA, Gratchev AN. Macrophage cytotoxic activity and its role in the tumor pathogenesis. Almanac of Clinical Medicine. 2022;50(1):13–20. (In Russ.). https://doi.org/10.18786/2072-0505-2022-50-008Aponte-López A, Muñoz-Cruz S. Mast Cells in the Tumor Microenvironment. Adv Exp Med Biol. 2020;1273:159–173. https://doi.org/10.1007/978-3-030-49270-0_9Aponte-López A, Muñoz-Cruz S. Mast Cells in the Tumor Microenvironment. Adv Exp Med Biol. 2020;1273:159–173. https://doi.org/10.1007/978-3-030-49270-0_9Акмаев И. Г. Нейроиммуноэндокринология: истоки и перспективы развития. Успехи физиологических наук. 2003;34(4):4–15.Akmayev IG. Neuroimmunoendocrinology, its developmental consideration. Progress in Physiological Science. 2003;34(4):4–15. (In Russ.).Бочарова О. А., Карпова Р. В., Бочаров Е. В., Вершинская А. А., Барышникова М. А., Казеев И. В., и др. Фитоадапто гены в биотерапии опухолей и гериатрии. (часть 1). Российский биотерапевтический журнал. 2020;19(2):13–21. https://doi.org/10.17650/1726-9784-2019-19-2-13-21Bocharova OA, Karpova RV, Bocharov EV, Vershinskaya AA, Baryshnikova MA, Kazeev IV, et al. Phytoadaptogens in the tumours biotherapy and geriatrics (part 1). Russian Journal of Biotherapy. 2020;19(2):13–21. (In Russ.). https://doi.org/10.17650/1726-9784-2019-19-2-13-21Garkavi LH. Zhukova GV, Shikhliarova AI, Evstratova OF, Barteneva TA, Gudzkova TN, et al. Antitumor action and other reg ulatory effects of low-intensity electromagnetic and chemical factors in an experiment. Biophysics. 2014;59(6):944–953. https://doi.org/10.1134/s0006350914060037Garkavi LH. Zhukova GV, Shikhliarova AI, Evstratova OF, Barteneva TA, Gudzkova TN, et al. Antitumor action and other regulatory effects of low-intensity electromagnetic and chemical factors in an experiment. Biophysics. 2014;59(6):944–953. https://doi.org/10.1134/s0006350914060037Zhou M, Tang Y, Xu W, Hao X, Li Y, Huang S, Xiang D, Wu J. Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies. Front Immunol. 2023;14:1140463. https://doi.org/10.3389/fimmu.2023.1140463Zhou M, Tang Y, Xu W, Hao X, Li Y, Huang S, Xiang D, Wu J. Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies. Front Immunol. 2023;14:1140463. https://doi.org/10.3389/fimmu.2023.1140463Гринько Е. K., Донецкова А. Д. Основные подходы к применению моноклональных антител в иммунотерапии злокачественных новообразований. Иммунология. 2024;45(3):355–366. https://doi.org/10.33029/1816-2134-2024-45-3-355-366Grinko EK, Donetskova AD. The main approaches for monoclonal antibodies in cancer immunotherapy. Immunologiya. 2024;45(3):355–366. (In Russ.). https://doi.org/10.33029/1816-2134-2024-45-3-355-366Zhu Y, Meng M, Hou Z, Wang W, Li L, Guan A, et al. Impact of cytotoxic T lymphocytes immunotherapy on prognosis of col orectal cancer patients. Front Oncol. 2023;13:1122669. https://doi.org/10.3389/fonc.2023.1122669Zhu Y, Meng M, Hou Z, Wang W, Li L, Guan A, et al. Impact of cytotoxic T lymphocytes immunotherapy on prognosis of colorectal cancer patients. Front Oncol. 2023;13:1122669. https://doi.org/10.3389/fonc.2023.1122669Hong H, He Y, Li Y, Shen Y, Qu Y. Clinical trial landscape for TIL therapy: emerging insights and future directions in oncology. J Transl Med. 2024;22(1):1008. https://doi.org/10.1186/s12967-024-05826-zHong H, He Y, Li Y, Shen Y, Qu Y. Clinical trial landscape for TIL therapy: emerging insights and future directions in oncology. J Transl Med. 2024;22(1):1008. https://doi.org/10.1186/s12967-024-05826-zHiltensperger M, Krackhardt AM. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells. Front Immunol. 2023;14:1121030. https://doi.org/10.3389/fimmu.2023.1121030Hiltensperger M, Krackhardt AM. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells. Front Immunol. 2023;14:1121030. https://doi.org/10.3389/fimmu.2023.1121030Сидорова С. С., Юкальчук Д. Ю., Пономаренко Д. М., Сидоров С. П., Казакова И. И., Тюменцева Е. С. Комбинация таргетной и иммунотерапии в первой линии метастатического светлоклеточного рака почки. Клинический слу чай. Эффективная фармакотерапия. 2022;18(35):16–21. https://doi.org/10.33978/2307-3586-2022-18-35-16-21Sidorova SS, Yukalchuk DYu, Ponomarenko DM, Sidorov SP, Kazakova II, Tyumentseva ES. Combination оf Targeted аnd Immunotherapy in the First Line оf Metastatic Clear Cell Kidney Cancer. Effective Pharmacotherapy. 2022;18(35):16–21. (In Russ.). https://doi.org/10.33978/2307-3586-2022-18-35-16-21Janeway CA, Travers JP, Walport M, Shlomchik MJ. Immunobiology, 5th edition. The Immune System in Health and Disease. New York: Garland Science; 2001.Janeway CA, Travers JP, Walport M, Shlomchik MJ. Immunobiology, 5th edition. The Immune System in Health and Disease. New York: Garland Science; 2001.Sareen G, Mohan M, Mannan A, Dua K, Singh TG. A new era of cancer immunotherapy: vaccines and miRNAs. Cancer Im munol Immunother. 2025;74(5):163. https://doi.org/10.1007/s00262-025-04011-5Sareen G, Mohan M, Mannan A, Dua K, Singh TG. A new era of cancer immunotherapy: vaccines and miRNAs. Cancer Immunol Immunother. 2025;74(5):163. https://doi.org/10.1007/s00262-025-04011-5Филин И. Ю., Китаева К. В., Ризванов А. А., Соловьева В. В. Современное состояние и перспективы развития им мунотерапии онкологических заболеваний с применением дендритных вакцин. Ученые записки Казанского университета. Серия: Естественные науки. 2022;164(3):347–366. https://doi.org/10.26907/2542-064X.2022.3.347-366Filin IYu, Kitaeva KV, Rizvanov AA, Solovyeva VV. Current state and prospects of using dendritic cell vaccination for cancer immunotherapy. Uchenye Zapiski Kazanskogo Universiteta. Seriya Estestvennye Nauki. 2022;164(3):347–366. (In Russ.). https://doi.org/10.26907/2542-064X.2022.3.347-366Salah A, Wang H, Li Y, Ji M, Ou WB, Qi N, Wu Y. Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clin ical Applications. Front Cell Dev Biol. 2021;9:686544. https://doi.org/10.3389/fcell.2021.686544Salah A, Wang H, Li Y, Ji M, Ou WB, Qi N, Wu Y. Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications. Front Cell Dev Biol. 2021;9:686544. https://doi.org/10.3389/fcell.2021.686544Kim MK, Kim J. Properties of immature and mature dendritic cells: phenotype, morphology, phagocytosis, and migration. RSC Adv. 2019;9(20):11230–11238. https://doi.org/10.1039/c9ra00818gKim MK, Kim J. Properties of immature and mature dendritic cells: phenotype, morphology, phagocytosis, and migration. RSC Adv. 2019;9(20):11230–11238. https://doi.org/10.1039/c9ra00818gSorino C, Iezzi S, Ciuffreda L, Falcone I. Immunotherapy in melanoma: advances, pitfalls, and future perspectives. Front Mol Biosci. 2024;11:1403021. https://doi.org/10.3389/fmolb.2024.1403021Sorino C, Iezzi S, Ciuffreda L, Falcone I. Immunotherapy in melanoma: advances, pitfalls, and future perspectives. Front Mol Biosci. 2024;11:1403021. https://doi.org/10.3389/fmolb.2024.1403021Wilgenhof S, Corthals J, Van Nuffel AM, Benteyn D, Heirman C, Bonehill A, et al. Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. Cancer Immunol Immunother. 2015;64(3):381–388. https://doi.org/10.1007/s00262-014-1642-8Wilgenhof S, Corthals J, Van Nuffel AM, Benteyn D, Heirman C, Bonehill A, et al. Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. Cancer Immunol Immunother. 2015;64(3):381–388. https://doi.org/10.1007/s00262-014-1642-8Балдуева И. А., Новик А. В., Моисеенко В. М., Нехаева Т. Л., Данилова А. Б., Данилов А. О., и др. Клиническое ис следование (II фаза) вакцины на основе аутологичных дендритных клеток с иммунологическим адъювантом у больных с меланомой кожи. Вопросы онкологии. 2012;58(2):212–221.Baldueva IA, Novik AV, Moiseenko VM, Nehaeva TL, Danilova AB, Danilov AO, et al. The results of second-phase clinical trial of autologous dendritic cells vaccine with immunologic adjuvant in cutaneous melanoma patients. Problems in Oncology. 2012;58(2):212–221. (In Russ.).Фадеев Ф. А., Замятин А. В., Седнева-Луговец Д. В., Микеров И. А., Губаева О. В. Получение дендритных клеток для терапии онкологических заболеваний. Вестник Уральской медицинской академии науки. 2020;17(4):347–353. https://doi.org/10.22138/2500-0918-2020-17-4-347-353Fadeyev FA, Zamyatin AV, Sedneva-Lugovets DV, Mikerov IA, Gubaeva OV. Generation of dendritic cells for cancer therapy. Journal of Ural Medical Academic Science. 2020;17(4):347–353. (In Russ.). https://doi.org/10.22138/2500-0918-2020-17-4-347-353Kugler A, Stuhler G, Walden P, Zöller G, Zobywalski A, Brossart P, et al. Regression of human metastatic renal cell carcino ma after vaccination with tumor cell-dendritic cell hybrids. Nat Med. 2000 Mar;6(3):332-6. doi: 10.1038/73193. Retraction in: Nat Med. 2003;9(9):1221. https://doi.org/10.1038/nm0903-1221aKugler A, Stuhler G, Walden P, Zöller G, Zobywalski A, Brossart P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med. 2000 Mar;6(3):332-6. doi: 10.1038/73193. Retraction in: Nat Med. 2003;9(9):1221. https://doi.org/10.1038/nm0903-1221aLee KW, Yam JWP, Mao X. Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations. Cells. 2023; 12(17):2147. https://doi.org/10.3390/cells12172147Lee KW, Yam JWP, Mao X. Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations. Cells. 2023; 12(17):2147. https://doi.org/10.3390/cells12172147Злокачественные новообразования в России в 2023 году (заболеваемость и смертность). Под редакцией А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиоло гии» Минздрава России; 2024, 276 с. Доступно по: https://oncology-association.ru/wp-content/uploads/2024/08/zis-2023-elektronnaya-versiya.pdfMalignant neoplasms in Russia in 2020 (morbidity and mortality). Edited by Kaprin AD, Starinsky VV, Shakhzadova AO. Мoscow: P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation, 2024, 276 p. (In Russ.). Availble at: https://oncology-association.ru/wp-content/uploads/2024/08/zis-2023-elektronnaya-versiya.pdfKremer WW, Dick S, Heideman DAM, Steenbergen RDM, Bleeker MCG, Verhoeve HR, et al. Clinical Regression of High-Grade Cervical Intraepithelial Neoplasia Is Associated with Absence of FAM19A4/miR124-2 DNA Methylation (CONCERVE Study). J Clin Oncol. 2022;40(26):3037–3046. https://doi.org/10.1200/JCO.21.02433Kremer WW, Dick S, Heideman DAM, Steenbergen RDM, Bleeker MCG, Verhoeve HR, et al. Clinical Regression of High-Grade Cervical Intraepithelial Neoplasia Is Associated with Absence of FAM19A4/miR124-2 DNA Methylation (CONCERVE Study). J Clin Oncol. 2022;40(26):3037–3046. https://doi.org/10.1200/JCO.21.02433Столбовой А. В., Ислим Н., Лойко И. Е., Зверева Д. П., Собина С.С. Проблемы в лечении рака шейки матки. Клини ческий разбор в общей медицине. 2024;5(7):59–68. https://doi.org/10.47407/kr2024.5.7.00448Stolbovoy AV, Islim N, Loiko IE, Zvereva DP, Sobina SS. Issues in the treatment of cervix uteri. Clinical Analysis in General Medicine. 2024;5(7):59–68. (In Russ.). https://doi.org/10.47407/kr2024.5.7.00448Anca-Stanciu MB, Manu A, Olinca MV, Coroleucă C, Comandașu DE, Coroleuca CA, et al. Comprehensive Review of En dometrial Cancer: New Molecular and FIGO Classification and Recent Treatment Changes. J Clin Med. 2025;14(4):1385. https://doi.org/10.3390/jcm14041385Anca-Stanciu MB, Manu A, Olinca MV, Coroleucă C, Comandașu DE, Coroleuca CA, et al. Comprehensive Review of Endometrial Cancer: New Molecular and FIGO Classification and Recent Treatment Changes. J Clin Med. 2025;14(4):1385. https://doi.org/10.3390/jcm14041385Motohara T., Yoshida G.J., Katabuchi H. The hallmarks of ovarian cancer stem cells and niches: Exploring their harmonious interplay in therapy resistance. Semin Cancer Biol. 2021 Dec;77:182–193. https://doi.org/10.1016/j.semcancer.2021.03.038Motohara T., Yoshida G.J., Katabuchi H. The hallmarks of ovarian cancer stem cells and niches: Exploring their harmonious interplay in therapy resistance. Semin Cancer Biol. 2021 Dec;77:182–193. https://doi.org/10.1016/j.semcancer.2021.03.038Longoria TC, Eskander RN. Immunotherapy in endometrial cancer – an evolving therapeutic paradigm. Gynecol Oncol Res Pract. 2015;2:11. https://doi.org/10.1186/s40661-015-0020-3Longoria TC, Eskander RN. Immunotherapy in endometrial cancer – an evolving therapeutic paradigm. Gynecol Oncol Res Pract. 2015;2:11. https://doi.org/10.1186/s40661-015-0020-3Truxova I, Kasikova L, Hensler M, Skapa P, Laco J, Pecen L, et al. Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. J Immunother Cancer. 2018 Dec 4;6(1):139. https://doi.org/10.1186/s40425-018-0446-3Truxova I, Kasikova L, Hensler M, Skapa P, Laco J, Pecen L, et al. Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. J Immunother Cancer. 2018 Dec 4;6(1):139. https://doi.org/10.1186/s40425-018-0446-3Румянцев А. А., Анохин А. Ю. Роль иммунотерапии в лечении метастатических и рецидивирующих новообразований женской репродуктивной системы. Медицинский совет. 2021;(9):76–86. https://doi.org/10.21518/2079-701X-2021-9-76-86Rumyantsev AA, Anokhin AY. The role of immunotherapy in the management of metastatic/recurrent female reproductive system neoplasms. Medical Council. 2021;(9):76–86. (In Russ.). https://doi.org/10.21518/2079-701X-2021-9-76-86Zhang W, Liu Y-M, Li D, Liu S, Cai X-J, Tang J-Y, et al. Research progress on tumor-infiltrating lymphocyte therapy for cervi cal cancer. 2025; Front. Immunol. 16:1524842. https://doi.org/10.3389/fimmu.2025.1524842Zhang W, Liu Y-M, Li D, Liu S, Cai X-J, Tang J-Y, et al. Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer. 2025; Front. Immunol. 16:1524842. https://doi.org/10.3389/fimmu.2025.1524842Водолажский Д. И., Меньшенина А. П., Двадненко К. В., Новикова И. А., Златник Е. Ю., Бахтин А. В., и др. Опыт конструиро вания дендритно-клеточной вакцины для лечения рака шейки матки. Фундаментальные исследования. 2015;1-4:716–720.Vodolazhskiy DI, Menshenina AP, Dvadnenko KV, Novikova IA, Zlatnik EYu, Bakhtin AV, et al. Experience of dendritic cell vaccine design for cervical cancer treatment. Fundamental Research. 2015;1-4:716–720. (In Russ.).Меньшенина А. П., Златник Е. Ю., Сагакянц А. Б., Моисеенко Т. И., Ушакова Н. Д., Франциянц Е. М., и др. Новые возможности иммунокоррекции у больных раком шейки матки в комплексном лечении. Российский иммуно логический журнал. 2021;24(1):115–122. https://doi.org/10.46235/1028-7221-373-nooMenshenina AP, Zlatnik EYu, Sagakyants AB, Moiseenko TI, Ushakova ND, Frantsiyants EM, et al. New opportunities of immunocorrection in complex treatment of cervical cancer patients. Russian Journal of Immunology (RJI). 2021;24(1):115– 122. (In Russ.). https://doi.org/10.46235/1028-7221-373-nooМеньшенина АП. Новые подходы к лечению больных распространенным раком шейки матки. Дисс. Ростов-на-Дону, 2022.Menshenina AP. New approaches to the treatment of patients with advanced cervical cancer. Dissertation. Rostov-on-Don, 2022. (In Russ.).Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, et al. 618 Hpv16/18 E7-Pulsed Dendritic Cell Vaccination in Patients With Recurrent Cervical Cancer Refractory to Standard Salvage Therapy. Gynecol Oncol. 2006; 100(3):469–478. https://doi.org/10.1016/j.ygyno.2005.09.040.Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, et al. 618 Hpv16/18 E7-Pulsed Dendritic Cell Vaccination in Patients With Recurrent Cervical Cancer Refractory to Standard Salvage Therapy. Gynecol Oncol. 2006; 100(3):469–478. https://doi.org/10.1016/j.ygyno.2005.09.040.Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A, Siegel ER, et al. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol. 2008;82(4):1968– 1979. https://doi.org/10.1128/JVI.02343-07Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A, Siegel ER, et al. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol. 2008;82(4):1968– 1979. https://doi.org/10.1128/JVI.02343-07Chen B, Liu L, Xu H. Effectiveness of immune therapy combined with chemotherapy on the immune function and recurrence rate of cervical cancer. Exp Ther Med. 2015;9:1063–1067. https://doi.org/10.3892/etm.2015.2217Chen B, Liu L, Xu H. Effectiveness of immune therapy combined with chemotherapy on the immune function and recurrence rate of cervical cancer. Exp Ther Med. 2015;9:1063–1067. https://doi.org/10.3892/etm.2015.2217Ramanathan P, Ganeshrajah S, Raghanvan RK, Singh SS, Thangarajan R. Development and clinical evaluation of dendritic cell vaccines for HPV related cervical cancer – a feasibility study. Asian Pac J Cancer Prev. 2014;15(14):5909–5916. https://doi.org/10.7314/apjcp.2014.15.14.5909Ramanathan P, Ganeshrajah S, Raghanvan RK, Singh SS, Thangarajan R. Development and clinical evaluation of dendritic cell vaccines for HPV related cervical cancer – a feasibility study. Asian Pac J Cancer Prev. 2014;15(14):5909–5916. https://doi.org/10.7314/apjcp.2014.15.14.5909Dhandapani H, Jayakumar H, Seetharaman A, Singh SS, Ganeshrajah S, Jagadish N, et al. Dendritic cells matured with recombinant human sperm associated antigen 9 (rhSPAG9) induce CD4+, CD8+ T cells and activate NK cells: a potential candidate molecule for immunotherapy in cervical cancer. Cancer Cell Int. 2021 Sep 7;21(1):473. https://doi.org/10.1186/s12935-021-01951-7Dhandapani H, Jayakumar H, Seetharaman A, Singh SS, Ganeshrajah S, Jagadish N, et al. Dendritic cells matured with recombinant human sperm associated antigen 9 (rhSPAG9) induce CD4+, CD8+ T cells and activate NK cells: a potential candidate molecule for immunotherapy in cervical cancer. Cancer Cell Int. 2021 Sep 7;21(1):473. https://doi.org/10.1186/s12935-021-01951-7Zhou X, Lian H, Li H, Fan M, Xu W, Jin Y. Nanotechnology in cervical cancer immunotherapy: Therapeutic vaccines and adoptive cell therapy. Front Pharmacol. 2022;13:1065793. https://doi.org/10.3389/fphar.2022.1065793Zhou X, Lian H, Li H, Fan M, Xu W, Jin Y. Nanotechnology in cervical cancer immunotherapy: Therapeutic vaccines and adoptive cell therapy. Front Pharmacol. 2022;13:1065793. https://doi.org/10.3389/fphar.2022.1065793Di Dio C, Bogani G, Di Donato V, Cuccu I, Muzii L, Musacchio L, et al. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma. Gynecol. Oncol. 2023;169:27–33. https://doi.org/10.1016/j.ygyno.2022.11.031Di Dio C, Bogani G, Di Donato V, Cuccu I, Muzii L, Musacchio L, et al. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma. Gynecol. Oncol. 2023;169:27–33. https://doi.org/10.1016/j.ygyno.2022.11.031Coosemans A, Tuyaerts S, Vanderstraeten A, Vergote I, Amant F, Van Gool SW. Dendritic cell immunotherapy in uterine cancer. Hum Vaccin Immunother. 2014;10(7):1822–1827. https://doi.org/10.4161/hv.28716Coosemans A, Tuyaerts S, Vanderstraeten A, Vergote I, Amant F, Van Gool SW. Dendritic cell immunotherapy in uterine cancer. Hum Vaccin Immunother. 2014;10(7):1822–1827. https://doi.org/10.4161/hv.28716Agarwal A, Yadav S, Dusane R, Menon S, Rekhi B, Deodhar KK. Endometrial serous carcinoma: A retrospective review of histological features & their clinicopathological association with disease-free survival & overall survival. Indian J Med Res. 2022;156(1):83–93. https://doi.org/10.4103/ijmr.IJMR_697_20Agarwal A, Yadav S, Dusane R, Menon S, Rekhi B, Deodhar KK. Endometrial serous carcinoma: A retrospective review of histological features & their clinicopathological association with disease-free survival & overall survival. Indian J Med Res. 2022;156(1):83–93. https://doi.org/10.4103/ijmr.IJMR_697_20Santin AD, Hermonat PL, Ravaggi A, Bellone S, Cowan C, Coke C, Pecorelli S, et al. Development and therapeutic effect of adoptively transferred T cells primed by tumor lysate-pulsed autologous dendritic cells in a patient with metastatic endo metrial cancer. Gynecol Obstet Invest. 2000; 49(3):194–203. https://doi.org/10.1159/000010246Santin AD, Hermonat PL, Ravaggi A, Bellone S, Cowan C, Coke C, Pecorelli S, et al. Development and therapeutic effect of adoptively transferred T cells primed by tumor lysate-pulsed autologous dendritic cells in a patient with metastatic endometrial cancer. Gynecol Obstet Invest. 2000; 49(3):194–203. https://doi.org/10.1159/000010246Santin AD, Bellone S, Ravaggi A, Roman JJ, Pecorelli S, Parham GP, Cannon MJ. Induction of tumour-specific CD8(+) cyto toxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer. Br J Cancer. 2002;86(1):151–157. https://doi.org/10.1038/sj.bjc.6600026Santin AD, Bellone S, Ravaggi A, Roman JJ, Pecorelli S, Parham GP, Cannon MJ. Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer. Br J Cancer. 2002;86(1):151–157. https://doi.org/10.1038/sj.bjc.6600026Coosemans A, Wölfl M, Berneman ZN, Van Tendeloo V, Vergote I, Amant F, Van Gool SW. Immuno-logical response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma. Anticancer Res. 2010;30:3709–3714.Coosemans A, Wölfl M, Berneman ZN, Van Tendeloo V, Vergote I, Amant F, Van Gool SW. Immuno-logical response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma. Anticancer Res. 2010;30:3709–3714.Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman ZN, et al., VAN Gool SW. Wilms’ Tumor Gene 1 (WT1)-loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial. Anticancer Res. 2013; 33:5495–5500.Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman ZN, et al., VAN Gool SW. Wilms’ Tumor Gene 1 (WT1)-loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial. Anticancer Res. 2013; 33:5495–5500.Rodolakis A, Scambia G, Planchamp F, Acien M, Di Spiezio Sardo A, Farrugia M, et al. ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma. Hum Reprod Open. 2023 Feb 6;2023(1):hoac057. https://doi.org/10.1093/hropen/hoac057.Rodolakis A, Scambia G, Planchamp F, Acien M, Di Spiezio Sardo A, Farrugia M, et al. ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma. Hum Reprod Open. 2023 Feb 6;2023(1):hoac057. https://doi.org/10.1093/hropen/hoac057.Koeneman BJ, Schreibelt G, Gorris MAJ, Hins-de Bree S, Westdorp H, Ottevanger PB, de Vries IJM. Dendritic cell vaccina tion combined with carboplatin/paclitaxel for metastatic endometrial cancer patients: results of a phase I/II trial. Front Immunol. 2024;15:1368103. https://doi.org/10.3389/fimmu.2024.1368103Koeneman BJ, Schreibelt G, Gorris MAJ, Hins-de Bree S, Westdorp H, Ottevanger PB, de Vries IJM. Dendritic cell vaccination combined with carboplatin/paclitaxel for metastatic endometrial cancer patients: results of a phase I/II trial. Front Immunol. 2024;15:1368103. https://doi.org/10.3389/fimmu.2024.1368103Глузман М. И., Тюкавина Н. В., Руденко Д. С., Орлова Р. В. Иммунотерапия рака яичников: нестандартное решение – нестандартный ответ. Клинический случай в онкологии. 2023;1(1):49–55. http://dx.doi.org/10.62546/3034-1477-2023-1-1-49-55Gluzman MI, Tyukavina NV, Rudenko DS, Orlova RV. Ovarian cancer immunotherapy: non-standard solution – non-standard respons. Clinical Case in Oncology. 2023;1(1):49–55. (In Russ.). http://dx.doi.org/10.62546/3034-1477-2023-1-1-49-55Шубина И. Ж., Грицай А. Н., Мамедова Л. Т., Соколов Н. Ю., Кузнецов С. А., Возможности иммунотерапии при раке яичников. Опухоли женской репродуктивной системы. 2013;3–4:110–113. https://doi.org/10.17650/1994-4098-2013-0-3-4-110-113Shubina IZh, Gritsay AN, Mamedova LT, Sokolov NYu, Kuznetsov SA, Kiselevskiy MV, et al. Imunotherapy opportunities in ovarian cancer. Tumors of female reproductive system. 2013;3–4:110–113. (In Russ.). https://doi.org/10.17650/1994-4098-2013-0-3-4-110-113Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, et al. Phase I/II randomized trial of dendritic cell vacci nation with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol. Immunother. 2012;61(5):629–641. https://doi.org/10.1186/1757-2215-7-48Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol. Immunother. 2012;61(5):629–641. https://doi.org/10.1186/1757-2215-7-48Kobayashi M, Chiba A, Izawa H, Yanagida E, Okamoto M, Shimodaira S, et al. DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT). The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized pep-tides for recurrent ovarian cancer. J Ovarian Res. 2014;7:48. https://doi.org/10.1186/1757-2215-7-48Kobayashi M, Chiba A, Izawa H, Yanagida E, Okamoto M, Shimodaira S, et al. DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT). The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized pep-tides for recurrent ovarian cancer. J Ovarian Res. 2014;7:48. https://doi.org/10.1186/1757-2215-7-48Zhang W, Lu X, Cui P, Piao C, Xiao M, Liu X, et al. Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccina tion-based immunotherapy in patients with advanced cancer. Cancer Immunol Immunother. 2019;68(1):121–130. https://doi.org/10.1007/s00262-018-2257-2Zhang W, Lu X, Cui P, Piao C, Xiao M, Liu X, et al. Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer. Cancer Immunol Immunother. 2019;68(1):121–130. https://doi.org/10.1007/s00262-018-2257-2Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, et al. A dendritic cell vaccine pulsed with autologous hypochlorous acid- oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res. 2013 Sep 1;19(17):4801–4815. https://doi.org/10.1158/1078-0432.ccr-13-1185Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, et al. A dendritic cell vaccine pulsed with autologous hypochlorous acid- oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res. 2013 Sep 1;19(17):4801–4815. https://doi.org/10.1158/1078-0432.ccr-13-1185Vlad AM, Budiu RA, Lenzner DE, Wang Y, Thaller JA, Colonello K, et al. A phase II trial of intraperitoneal interleukin-2 in pa tients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother. 2010 Feb;59(2):293–301. https://doi.org/10.1007/s00262-009-0750-3Vlad AM, Budiu RA, Lenzner DE, Wang Y, Thaller JA, Colonello K, et al. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother. 2010 Feb;59(2):293– 301. https://doi.org/10.1007/s00262-009-0750-3Sasada A, Abe M, Abe H. A case of advanced ovarian cancer effectively treated with a combination of multi-peptide den dritic cell immunotherapy, surgery, and chemotherapy. Personalized Medicine Universe. 2017;6:28–30. https://doi.org/10.1016/j.pmu.2017.04.003Sasada A, Abe M, Abe H. A case of advanced ovarian cancer effectively treated with a combination of multi-peptide dendritic cell immunotherapy, surgery, and chemotherapy. Personalized Medicine Universe. 2017;6:28–30. https://doi.org/10.1016/j.pmu.2017.04.003Guo Q, Yang Q, Li J, Liu G, Nikoulin I, Jia S. Advanced clinical trials of dendritic cell vaccines in ovarian cancer. J Investig Med. 2020;68(7):1223–1227. https://doi.org/10.1136/jim-2020-001355Guo Q, Yang Q, Li J, Liu G, Nikoulin I, Jia S. Advanced clinical trials of dendritic cell vaccines in ovarian cancer. J Investig Med. 2020;68(7):1223–1227. https://doi.org/10.1136/jim-2020-001355Caro AA, Deschoemaeker S, Allonsius L, Coosemans A, Laoui D. Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer. Cancers (Basel). 2022;14(16):4037. https://doi.org/10.3390/cancers14164037Caro AA, Deschoemaeker S, Allonsius L, Coosemans A, Laoui D. Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer. Cancers (Basel). 2022;14(16):4037. https://doi.org/10.3390/cancers14164037Zhang X, He T, Li Y, Chen L, Liu H, Wu Y, Guo H. Dendritic Cell Vaccines in Ovarian Cancer. Front Immunol. 2021 Jan 25;11:613773. https://doi.org/10.3389/FIMMU.2020.613773/BIBTEX/Zhang X, He T, Li Y, Chen L, Liu H, Wu Y, Guo H. Dendritic Cell Vaccines in Ovarian Cancer. Front Immunol. 2021 Jan 25;11:613773. https://doi.org/10.3389/FIMMU.2020.613773/BIBTEX/Dang BN, Kwon TK, Lee S, Jeong JH, Yook S. Nanoparticle-based immunoengineering strategies for enhancing cancer im munotherapy. J Control Release. 2024;365:773–800. https://doi.org/10.1016/j.jconrel.2023.12.007Dang BN, Kwon TK, Lee S, Jeong JH, Yook S. Nanoparticle-based immunoengineering strategies for enhancing cancer immunotherapy. J Control Release. 2024;365:773–800. https://doi.org/10.1016/j.jconrel.2023.12.007Mehrani Y, Morovati S, Keivan F, Sarmadi S, Shojaei S, Forouzanpour D, et al. Dendritic Cell-Based Cancer Vaccines: The Impact of Modulating Innate Lymphoid Cells on Anti-Tumor Effi-cacy. Cells. 2025;14(11):812. https://doi.org/10.3390/cells14110812.Mehrani Y, Morovati S, Keivan F, Sarmadi S, Shojaei S, Forouzanpour D, et al. Dendritic Cell-Based Cancer Vaccines: The Impact of Modulating Innate Lymphoid Cells on Anti-Tumor Effi-cacy. Cells. 2025;14(11):812. https://doi.org/10.3390/cells14110812.

The authors declare that there are no conflicts of interest present.